Why join a multicentre breast cancer trial?

Por Grieve, R J
Publicado em 1979

Dysphagia: a further symptom of hypercalcaemia?

Por Grieve, R J, Dixon, P F
Publicado em 1983

Hypoparathyroidism and hypocalcaemia occurring during cancer chemotherapy.

Por Grieve, R J, Roberts, H, Dixon, P F, Hunter, R D
Publicado em 1982

A preliminary comparison of total skin electron treatment techniques to demonstrate the application of a mid-torso phantom for measurement of dose penetration

Por Baugh, G, Al-Alawi, T, Fletcher, C L, Mills, J A, Grieve, R J
Publicado em 2011

Effect of sodium butyrate on synthesis of specific proteins by human breast-carcinoma cells.

Por Grieve, R. J., Woods, K. L., Mann, P. R., Smith, S. C., Wilson, G. D., Howell, A.
Publicado em 1980

Tumour markers in breast cancer.

Por Cove, D. H., Woods, K. L., Smith, S. C., Burnett, D., Leonard, J., Grieve, R. J., Howell, A.
Publicado em 1979

Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer

Por Grammatopoulos, D, Elliott, Y, Smith, S C, Brown, I, Grieve, R J, Hillhouse, E W, Levine, M A, Ringel, M D
Publicado em 2003

West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. I. Patients with involved axillary lymph...

Por Morrison, J. M., Howell, A., Kelly, K. A., Grieve, R. J., Monypenny, I. J., Walker, R. A., Waterhouse, J. A.
Publicado em 1989

West Midlands Oncology Association trials of adjuvant chemotherapy in operable breast cancer: results after a median follow-up of 7 years. II. Patients without involved axillary ly...

Por Morrison, J. M., Howell, A., Kelly, K. A., Grieve, R. J., Monypenny, I. J., Walker, R. A., Waterhouse, J. A.
Publicado em 1989

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

Por Cameron, D A, Anderson, A, Toy, E, Evans, T R J, Le Vay, J H, Kennedy, I C S, Grieve, R J, Perren, T J, Jones, A, Mansi, J, Crown, J, Leonard, R C F
Publicado em 2002

NEAT: National Epirubicin Adjuvant Trial – toxicity, delivered dose intensity and quality of life

Por Earl, H M, Hiller, L, Dunn, J A, Bathers, S, Harvey, P, Stanley, A, Grieve, R J, Agrawal, R K, Fernando, I N, Brunt, A M, McAdam, K, O'Reilly, S, Rea, D W, Spooner, D, Poole, C J
Publicado em 2008